Haloperidol Noumed Life Sciences

Haloperidol Noumed Life Sciences is an oral medication containing the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in tablet form without a specified strength and is marketed in the European Union as a prescription‑only product. The drug works as a dopamine D2 receptor antagonist and is used under medical supervision for several psychiatric conditions. It is intended for adult patients and should be prescribed by a healthcare professional.

Haloperidol Noumed Life Sciences is indicated for several psychiatric disorders where dopamine blockade is beneficial.

- Schizophrenia, including maintenance therapy for chronic positive and negative symptoms. - Acute psychotic episodes associated with mood disorders or substance‑induced states. - Tourette syndrome to reduce both motor and vocal tics when other therapies are insufficient. - Severe agitation or aggression in an inpatient or emergency setting, often as a short‑term measure. - Adjunctive treatment of other psychotic conditions, such as brief psychotic disorder, as determined by a clinician.

Side effects of haloperidol may vary in frequency and severity, and they should be monitored during treatment.

Common: - Drowsiness or sedation, which may affect alertness and driving ability. - Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (restlessness). - Dry mouth, increased salivation, and other anticholinergic‑type effects. - Constipation, abdominal discomfort, or reduced gastrointestinal motility.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal condition marked by high fever, muscle rigidity, and autonomic instability. - Tardive dyskinesia, a potentially irreversible movement disorder presenting as repetitive, involuntary facial or limb movements. - Cardiac effects including QT interval prolongation that can predispose to serious arrhythmias.

Before initiating haloperidol therapy, clinicians should evaluate several precautionary factors to minimize risks.

- Assess patient history for cardiovascular disease, especially conditions that predispose to QT prolongation. - Evaluate for a personal or family history of movement disorders such as tardive dyskinesia. - Use caution in patients with hepatic or renal impairment, adjusting dose as appropriate. - Monitor for signs of neuroleptic malignant syndrome, especially during rapid dose escalation. - Consider pregnancy and lactation status; haloperidol is classified as pregnancy category unknown and should be used only when benefits outweigh risks. - Review concomitant medications that may increase the risk of extrapyramidal symptoms or cardiac effects.

Haloperidol can interact with other medicines, altering its effectiveness or increasing the likelihood of adverse reactions.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may amplify extrapyramidal side effects. - Medications that significantly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels. - Antihistamines with QT‑prolonging potential, such as terfenadine, that may increase cardiac risk.

Use with caution: - CNS depressants including benzodiazepines, opioids, or alcohol, which can enhance sedation. - CYP2D6 substrates (e.g., metoprolol, fluoxetine) that may compete for metabolism. - Anticholinergic agents, which may mask early signs of extrapyramidal symptoms. - Lithium therapy, as combined use may increase neurotoxic effects. - Anticholinergic agents, which may mask early signs of extrapyramidal symptoms.